

20 March 2026

Gastroenterology New Patients

I would like to raise an FOI request: How many new patients were treated by the Trust's Gastroenterology Department in the latest 3-month period of November, December and January (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Crohn's disease and Ulcerative colitis? I have provided a table below. Some treatments can only be used for one condition, which I have blocked out.

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st November 2025, they are not classed as a new patient for the purposes of this question.

Adult Services

	Total Gastroenterology Department	Crohn's Disease	Ulcerative Colitis
Adalimumab [Humira]	11	11	0
Adalimumab [All Biosimilar]	275	254	21
Etrasimod	0		0
Filgotinib	20		20
Golimumab	5	0	5
Guselkumab			
Infliximab [Remicade]	40	28	12
Infliximab [All Biosimilar]	252	210	42
Mirikizumab	35	<5	33
Ozanimod	<5		<5
Risankizumab	63	63	0
Tofacitinib	<5		<5
Upadacitinib	96	57	39
Ustekinumab [Stelara]	7	6	<5
Ustekinumab [All Biosimilar]	282	221	61
Vedolizumab	128	34	94

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

20 March 2026

Paediatric Service

	Total Gastroenterology Department	Crohn's Disease	Ulcerative Colitis
Adalimumab [Humira]	0	0	0
Adalimumab [All Biosimilar]	0	0	0
Etrasimod	0		0
Filgotinib	0		0
Golimumab	0	0	0
Guselkumab	0	0	0
Infliximab [Remicade]	0	0	0
Infliximab [All Biosimilar]	11	5	<5
Mirikizumab	0	0	0
Ozanimod	0		0
Risankizumab	0	0	0
Tofacitinib	0		0
Upadacitinib	0	0	0
Ustekinumab [Stelara]	0	0	0
Ustekinumab [All Biosimilar]	<5	0	0
Vedolizumab	0	0	0